Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B

Table 1 Baseline characteristics of the enrolled patients n (%)

Characteristics	Clevudine(n = 118)	Entecavir(n = 136)	P-value
Age1, yr	42 ± 11	41 ± 11	0.358
Male gender	70 (59.3)	86 (63.2)	0.528
Cirrhosis	15 (12.7)	30 (22.1)	0.052
ALT2, IU/L	158 (107-263)	139.5 (101.5-288.5)	0.206
HBeAg-positive	88 (74.6)	94 (69.1)	0.322
HBV DNA level3, log10 copies/mL	7.3 ± 1.1	7.4 ± 1.1	0.556
Follow-up period3, wk	74 ± 24	75 ± 21	0.922

Data are presented by

¹mean ± SD;

²median (interquartile rang);

³median ± SD. ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.